Opiant’s nasal drug spray for opioid overdose gets FDA green light
HQ Team May 23, 2023: The FDA cleared Opiant Pharmaceuticals’ nasal spray to treat opioid overdose in adult and paediatric patients under the.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team May 23, 2023: The FDA cleared Opiant Pharmaceuticals’ nasal spray to treat opioid overdose in adult and paediatric patients under the.
HQ Team May 5, 2023: The USFDA has warned healthcare providers and consumers from using SD Biosensor Inc. pilot COVID-19 at-home tests due.
HQ Team May 2, 2023: Del Maguey Co., majority-owned by Pernod Ricard, will voluntarily recall certain ceramic ware artisan cups used to drink.
HQ Team May 2, 2023: TruVision Health, a US-based healthcare company, will recall its dozen unapproved dietary products after an FDA inspection found.
HQ Team April 26, 2023: The US Food and Drug Administration has cleared Biogen Inc’s drug, branded as Qalsody, to treat amyotrophic lateral.
HQ Team April 14, 2023: SAB Biotherapeutics got a fast-track designation from the USFDA for its investigational drug to treat influenza in high-risk.
HQ Team April 13, 2023: Fusion Pharmaceuticals, a Canada-based radiopharmaceuticals company, announced FDA clearance for its investigational new drug applications to treat solid.
HQ Team April 13, 2023: Merck KGaA announced the USFDA had put a hold on the initiation of new patients to test its.
HQ Team April 7, 2023: The FDA has withdrawn Netherland-based Covis Pharma’s drug meant to cut preterm birth as it failed to prove.
HQ Team April 3, 2023: BioNTech SE and Duality Biologics (Suzhou) have signed a $1.5 billion deal to develop and commercialise two cancer.